Latest Ras subfamily Stories
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO,
MANHATTAN BEACH, Calif., Jan.
CALGARY, Dec. 22, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
CALGARY, Dec. 2, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S.
Study May Lead to More Targeted Treatments for Cancers and "Rasopathies" CINCINNATI, Nov.
Focus on research and development for small molecule inhibitors of oncogenic K-Ras - the most commonly mutated oncogene in human cancers BOSTON and TOKYO, Nov.
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice.
Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and
A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.
- An imitative word; an onomatopoetic word.